Cardiovascular disease (CVD) is a potential adverse effect of endocrine treatment (ET) for prostate cancer (PC). We investigated absolute and relative CVD risk in 76,600 patients with PC undergoing ET ...

Empagliflozin vs placebo was associated with greater reductions in risk for cardiovascular disease among patients with type 1 diabetes. Sodium–glucose cotransporter inhibitors (SGLTis) are associated ...

Please provide your email address to receive an email when new articles are posted on . PREVENT is an online calculator that evaluates 10- and 30-year absolute risk associated with ...

A comparison of two risk prediction tools used to calculate an individual's risk of developing cardiovascular disease (CVD) suggests that the long-term, 30-year risk should be considered in addition ...

CHD is a leading cause of death in industrialized nations. Hyperlipidemia with elevated serum total cholesterol, LDL-C and triglycerides is a known major cardiovascular risk factor. HDL-C is ...

Please provide your email address to receive an email when new articles are posted on . CVD mortality is rising in the U.S. despite new therapies. Cross-specialty collaboration and innovative ...

Researchers provided comprehensive evidence of the benefits of statin use in elderly patients, addressing longstanding uncertainties. The robust evidence demonstrated that continuous statin therapy ...